A Randomized Trial of Contact Force in Atrial Flutter Ablation (CF-CTIA)

September 30, 2020 updated by: Mikkel Giehm-Reese, MD, Aarhus University Hospital Skejby
A clinical randomized trial to evaluate if CF guided Radio Frequency Ablation (RFA) to a specific of LSI in atrial flutter i superior to standard RFA.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Atrial flutter (AFL) is a macro-reentry tachycardia in the right atrium [1,2]. AFL is seen in 0,4 -1,2% of ECG´s in the hospital[3]. Prevalence is higher in patients with structural heart disease, as hypertension, coronary heart disease and cardiomyopathy and also in patients with chronic obstructive lung disease. AFL occurs frequently among patients operated for congenital heart disease.

Cavotricuspid isthmus ablation (CTIA) using radiofrequency (RF) energy is a well-established first line therapy of typical AFL.

The most common arrhythmia requiring treatment is atrial fibrillation (AF). When performing catheter ablation for AF, contact force (CF) applied during radiofrequency energy delivery is a powerful predictor of the electrical isolation of the pulmonary veins and of the clinical response. However, prospective data documenting the superiority of ablation guided by the real time CF monitoring over the standard procedure both for AF and for AFL, are missing. In this regard, showing superiority of ablation guided by the real time CF monitoring over the standard procedure in the simple lesion model of CTIA can serve as a proof of concept for more complex lesion sets, as in AF ablation. The Lesion Size Index (LSI) estimates the size of the lesion created by ablation. It takes account for the nonlinear relationship between the size of the lesion and its three main determinants (CF, power and duration [4,5]), and may therefore be an effective mean to precisely dose the amount of the delivered radiofrequency energy. This may prevent both insufficient lesion creation and complications due to excessive energy delivery. The aim of the present study is to evaluate if CF guided ablation targeting a specific value of LSI is superior to standard radiofrequency catheter ablation (RFCA).

Hypothesis:

CF guided ablation targeting a specific value of LSI is superior to standard RFCA with respect to creating lasting ablation lesions in the cavo-tricuspid isthmus region.

Purpose:

The present study is designed to determine if CF guided ablation targeting a specific value of LSI is superior to standard RFCA with respect to creating lasting ablation lesions in the cavo-tricuspid isthmus region.

Inclusion criteria:

Patients with typical AFL undergoing first CTIA are included.

Exclusion criteria:

Congenital heart disease AF is the dominant arrhythmia Prior right atrial atriotomy Significant mitral valve disease New York Heart Association (NYHA) class IV Secondary AFL (e.g. post-surgery, infections, hyperthyroidism) Age < 40 years Patient does not want to participate.

Study size:

156 patients.

Study design:

Randomized controlled double-blinded study

Inclusion and randomization:

Consecutive patients referred to Department of Cardiology, Aarhus University Hospital, Skejby for ablation of AFL will be screened. All pts without documented AF will undergo a 5 day ambulatory ECG before the scheduled ablation procedure.

Pts with AF documented either on a 12-lead ECG or during ambulatory ECG will be informed about pulmonary vein isolation, if suitable and in the case of accept will be referred for such.

Pts without documented AF fulfilling the inclusion criteria and pts who are not candidates for or not wanting Pulmonary Vein Isolation (PVI) will be invited to an interview with the daily contact person. They will here be informed about the study both orally and written. The interview will take place in a room specially selected for this interview to ensure there will be no interruptions. At the end of the interview pts will be asked to sign a written consent form. Subsequently patients are randomized (computer-based) to two Groups:

  1. In group 1, the ablation will be guided by real time CF monitoring and LSI, with a target LSI of 7,0 with a target range 6,8-7.2 . The aim will be a stable contact, and CF 10-30 g. Intermittent contact will be avoided.
  2. In group 2, the operator is blinded to the real-time CF.

Randomization Study data are recorded in a web-based case record form (CRF) with loggin of all data entries. The CRF is also used for randomization using computerized permuted blocks of different sizes. Randomization is stratified according to gender. An external data manager is responsible for the CRF and has programmed the random-number generator used.

Follow-up

4 weeks after ablation, a 5 day ambulatory ECG will be performed. 3 months after ablation an Electro Physiological study (EP) will be performed along with administration of adenosine to check the completeness of Bidirectional Isthmus Block (BDIB). In case of reconduction BDIB will be completed. Recurrent isthmus conduction will be classified as located in the anterior half of the isthmus, the posterior half of the isthmus or both.

The follow-up will be 12 months. Patients will be seen at the outpatient clinic 12 month after the ablation, where a 12-lead ECG will be performed. Before this 12 months' visit, a 5 day ambulatory ECG will be performed.

Study Type

Interventional

Enrollment (Actual)

156

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Aarhus, Denmark
        • Aarhus University Hospital, Skejby

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients with typical Atrial flutter undergoing first time Cavo Tricuspid Isthmus Ablation

Exclusion Criteria:

  • Congenital heart disease
  • Atrial fibrillation is the dominant arrhythmia
  • Prior right atrial atriotomy
  • Significant mitral valve disease
  • NYHA IV
  • Secondary AFL (e.g. post-surgery, infections, hyperthyroidism)
  • Age < 40 years

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention group
In the intervention group: The operator will perform the RFA treatment guided by real-time CF parameters.
Both groups will receive radiofrequency ablation treatment
Active Comparator: Control group
In the control group: The Operator will perform the RFA treatment blinded to the real-time CF parameters.
Both groups will receive radiofrequency ablation treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rate of recurrent isthmus conduction
Time Frame: 3 months
Rate of recurrent isthmus conduction measured at invasive electrophysiological study 3 months after ablation
3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rate of recurrent isthmus conduction in the anterior, middle or posterior third of the isthmus.
Time Frame: 3 months
Measured at invasive electrophysiological study 3 months after ablation
3 months
Freedom from recurrence of Atrial flutter
Time Frame: 3 and 12 months
Documented by either 12 lead ECG or ambulatory ECG
3 and 12 months
Occurrence of bidirectional isthmus block with the first ablation line.
Time Frame: 1 hour
Measured at the primary procedure
1 hour
Rate of permanent reconduction on the table
Time Frame: 10 minutes
Rate of permanent reconduction on the table spontaneous and with adenosine within a waiting period of 10 minutes.
10 minutes
Rate of transient reconduction on the table with adenosine
Time Frame: 10 minutes
Transient reconduction detected by administering adenosine
10 minutes
Ablation time needed to achieve bidirectional isthmus block
Time Frame: 1 hour
Evaluated at the end of the primary procedure
1 hour
Total ablation time
Time Frame: 1 hour
Evaluated at the end of the primary procedure
1 hour
Total procedure time
Time Frame: 1 hour
Evaluated at the end of the primary procedure
1 hour
Quality of Life assesing patients symptoms
Time Frame: 12 months
Quality of Life assessed by Short-Form-36 (SF-36) questionnaire
12 months
Contact Force (CF)
Time Frame: 1 hour
CF values measured in grams in the two groups
1 hour
Force-time-integral (FTI)
Time Frame: 1 hour
FTI values measured in gram seconds in the two groups
1 hour
Lesion-size-index (LSI)
Time Frame: 1 hour
LSI values measured in the two groups. LSI does not have a unit but is computed using the FTI value and the power (measured in watts) used during ablation.
1 hour
Reasons for reconduction
Time Frame: 3 months
Measuring % of poor ablations for patients with reconduction
3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Jens Cosedis Nielsen, MD, DMsci, Aarhus University Hospital Skejby

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2016

Primary Completion (Actual)

May 20, 2019

Study Completion (Actual)

June 1, 2020

Study Registration Dates

First Submitted

September 21, 2016

First Submitted That Met QC Criteria

September 26, 2016

First Posted (Estimate)

September 28, 2016

Study Record Updates

Last Update Posted (Actual)

October 5, 2020

Last Update Submitted That Met QC Criteria

September 30, 2020

Last Verified

November 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • CTIA-2016

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

IPD Plan Description

We are not authorized to share individual participant data

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe